Metabolic Dysfunction-Associated Steatohepatitis  >>  belapectin (GR-MD-02)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
belapectin (GR-MD-02) / Galectin Therap
NAVIGATE, NCT04365868: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2b
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc.
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
12/24
12/24
NCT02421094: Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis

Completed
2
30
US
GR-MD-02, galactoarabino-rhamnogalacturonate, Placebo
Galectin Therapeutics Inc.
Nonalcoholic Steatohepatitis
09/16
09/16
NASH-CX, NCT02462967: Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Checkmark Late-breaker data at The International Liver Congress 2018
Apr 2018 - Apr 2018: Late-breaker data at The International Liver Congress 2018
Checkmark Presentation of NASH CX trial (post hoc analysis) at EASL 2018 [screenshot]
Apr 2018 - Apr 2018: Presentation of NASH CX trial (post hoc analysis) at EASL 2018 [screenshot]
Checkmark From NASH-CX study for NASH cirrhosis without esophageal varices [screenshot]
More
Completed
2
162
US
GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Dr. Naga Chalasani, MD, Indiana University, Dr. Stephen A. Harrison, MD, Brooke Army Medical Center
Hypertension, Portal
10/17
10/17

Download Options